Literature DB >> 22574234

A 71-year-old man with a large cystic pancreatic mass.

Deborah Mukherji, Walid Faraj, Mohamed Khalife, Ali Shamseddine, Nadim El Majzoub, Ghazi Zaatari, Manish Shah, Ghassan K Abou-Alfa, Eileen M O'Reilly.   

Abstract

Entities:  

Year:  2012        PMID： 22574234      PMCID： PMC3348712     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  21 in total

1.  Clear cell "sugar" tumor of the pancreas. A novel member of the family of lesions characterized by the presence of perivascular epithelioid cells.

Authors:  G Zamboni; M Pea; G Martignoni; C Zancanaro; G Faccioli; E Gilioli; P Pederzoli; F Bonetti
Journal:  Am J Surg Pathol       Date:  1996-06       Impact factor: 6.394

2.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.

Authors:  Thierry Conroy; Françoise Desseigne; Marc Ychou; Olivier Bouché; Rosine Guimbaud; Yves Bécouarn; Antoine Adenis; Jean-Luc Raoul; Sophie Gourgou-Bourgade; Christelle de la Fouchardière; Jaafar Bennouna; Jean-Baptiste Bachet; Faiza Khemissa-Akouz; Denis Péré-Vergé; Catherine Delbaldo; Eric Assenat; Bruno Chauffert; Pierre Michel; Christine Montoto-Grillot; Michel Ducreux
Journal:  N Engl J Med       Date:  2011-05-12       Impact factor: 91.245

3.  Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study.

Authors:  Toru Furukawa; Günter Klöppel; N Volkan Adsay; Jorge Albores-Saavedra; Noriyoshi Fukushima; Akira Horii; Ralph H Hruban; Yo Kato; David S Klimstra; Daniel S Longnecker; Jutta Lüttges; G Johan A Offerhaus; Michio Shimizu; Makoto Sunamura; Arief Suriawinata; Kyoichi Takaori; Suguru Yonezawa
Journal:  Virchows Arch       Date:  2005-08-09       Impact factor: 4.064

Review 4.  Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival.

Authors:  De-rong Xie; Qiong Yang; Deng-lin Chen; Zhi-min Jiang; Zhuo-fei Bi; Wen Ma; Yuan-dong Zhang
Journal:  Jpn J Clin Oncol       Date:  2010-02-10       Impact factor: 3.019

5.  Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes.

Authors:  Nabil Wasif; David J Bentrem; James J Farrell; Clifford Y Ko; Oscar J Hines; Howard A Reber; James S Tomlinson
Journal:  Cancer       Date:  2010-07-15       Impact factor: 6.860

6.  Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer.

Authors:  M Cantore; C Rabbi; G Fiorentini; C Oliani; D Zamagni; C Iacono; A Mambrini; A Del Freo; A Manni
Journal:  Oncology       Date:  2004       Impact factor: 2.935

7.  The clear cell variant of solid pseudopapillary tumor of the pancreas: a previously unrecognized pancreatic neoplasm.

Authors:  Jorge Albores-Saavedra; Karen W Simpson; Seth J Bilello
Journal:  Am J Surg Pathol       Date:  2006-10       Impact factor: 6.394

8.  Clear cell endocrine pancreatic tumor mimicking renal cell carcinoma: a distinctive neoplasm of von Hippel-Lindau disease.

Authors:  M P Hoang; R H Hruban; J Albores-Saavedra
Journal:  Am J Surg Pathol       Date:  2001-05       Impact factor: 6.394

Review 9.  Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages.

Authors:  Sonja Gillen; Tibor Schuster; Christian Meyer Zum Büschenfelde; Helmut Friess; Jörg Kleeff
Journal:  PLoS Med       Date:  2010-04-20       Impact factor: 11.069

10.  Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study.

Authors:  A Demols; M Peeters; M Polus; R Marechal; F Gay; E Monsaert; A Hendlisz; J L Van Laethem
Journal:  Br J Cancer       Date:  2006-02-27       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.